We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline
News

Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline

Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline
News

Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genomatix Software GmbH (Munich) announced today that Sanofi-Aventis has renewed its licenses for Multi-Site access to the Genomatix Microarray Analysis Pipeline.

The pipeline provides a fully integrated, user friendly solution for the analysis of expression and tiling microarray experiments, including the powerful ChIP on chip studies.

Genomatix software module ChipInspector seamlessly integrates with additional modules (BiblioSphere PathwayEdition, ElDorado, Gene2Promoter, and GEMS Launcher) to achieve a molecular level understanding of how genes are regulated and co-regulated, providing the scientists at Sanofi-Aventis a comprehensive gene network and pathway analysis.

Martin Seifert, Vice President Microarray Business and Collaborative Research at Genomatix stated: “We are pleased that our existing relationship with Sanofi-Aventis has led to an extension of their existing licensing agreement.

It confirms the validity of our integrated approach to understanding gene regulation by combining state of the art software, biological data bases, expert systems and scientific support, to provide a complete solution for the computational biologist.”

Advertisement